Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
Subiela JD, de la Parra I, Taborda J, Medina AA, Pichler R, Krajewski W, Ojeda CM, Mardomingo AF, Durán PDO, Pérez EL, González-Padilla DA, Aumatell J, Mori K, Scilipoti P, Longoni M, de Angelis M, Caño-Velasco J, Puentedura AL, Pujol LP, Contieri R, Gallioli A, Tukiendorf A, D'Andrea D, Teoh JY, Afferi L, Del Giudice F, Marcq G, Albisinni S, Soria F, Mertens LS, Laukhtina E, Tully K, Mari A, Guerrero-Ramos F, Alvarez-Maestro M, Martín CC, Melendres FA, Buisan O, López-González JA, Dominguez-Escrig JL, Aranda J, Elena JLR, Basile G, Santos VGD, Moschini M, Pradere B, Acosta EA, Palacio FL, Puig AC, Gajate P, Saiz A, Gontero P, Revilla FJB; From Young Academic Urologist: Urothelial Carcinoma Working Group.
Subiela JD, et al. Among authors: de la parra i.
BJU Int. 2025 Aug 29. doi: 10.1111/bju.16913. Online ahead of print.
BJU Int. 2025.
PMID: 40883258